Azitra stock jumped 35.9% to $1.03, its best day in 7 months, after dosing the first patient in a Phase 1/2 trial of ATR04-484, a therapy for cancer drug-linked rashes. The FDA has granted Fast Track status to the program, which targets side effects affecting ~150,000 US patients annually. Retail sentiment turned 'extremely bullish'.